Cargando…

Toward transplantation tolerance with adipose tissue-derived therapeutics

Solid organ and composite tissue allotransplanation have been widely applied to treat end-stage organ failure and massive tissue defects, respectively. Currently there are a lot of research endeavors focusing on induction of transplantation tolerance, to relieve the burden derived from long-term imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Hui-Yun, Anggelia, Madonna Rica, Lin, Cheng-Hung, Wei, Fu-Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175575/
https://www.ncbi.nlm.nih.gov/pubmed/37187733
http://dx.doi.org/10.3389/fimmu.2023.1111813
_version_ 1785040237736493056
author Cheng, Hui-Yun
Anggelia, Madonna Rica
Lin, Cheng-Hung
Wei, Fu-Chan
author_facet Cheng, Hui-Yun
Anggelia, Madonna Rica
Lin, Cheng-Hung
Wei, Fu-Chan
author_sort Cheng, Hui-Yun
collection PubMed
description Solid organ and composite tissue allotransplanation have been widely applied to treat end-stage organ failure and massive tissue defects, respectively. Currently there are a lot of research endeavors focusing on induction of transplantation tolerance, to relieve the burden derived from long-term immunosuppressant uptake. The mesenchymal stromal cells (MSCs) have been demonstrated with potent immunomodulatory capacities and applied as promising cellular therapeutics to promote allograft survival and induce tolerance. As a rich source of adult MSCs, adipose tissue provides additional advantages of easy accessibility and good safety profile. In recent years, the stromal vascular fraction (SVF) isolated from adipose tissues following enzymatic or mechanical processing without in vitro culture and expansion has demonstrated immunomodulatory and proangiogenic properties. Furthermore, the secretome of AD-MSCs has been utilized in transplantation field as a potential “cell-free” therapeutics. This article reviews recent studies that employ these adipose-derived therapeutics, including AD-MSCs, SVF, and secretome, in various aspects of organ and tissue allotransplantation. Most reports validate their efficacies in prolonging allograft survival. Specifically, the SVF and secretome have performed well for graft preservation and pretreatment, potentially through their proangiogenic and antioxidative capacities. In contrast, AD-MSCs were suitable for peri-transplantation immunosuppression. The proper combination of AD-MSCs, lymphodepletion and conventional immunosuppressants could consistently induce donor-specific tolerance to vascularized composite allotransplants (VCA). For each type of transplantation, optimizing the choice of therapeutics, timing, dose, and frequency of administration may be required. Future progress in the application of adipose-derived therapeutics to induce transplantation tolerance will be further benefited by continued research into their mechanisms of action and the development of standardized protocols for isolation methodologies, cell culture, and efficacy evaluation.
format Online
Article
Text
id pubmed-10175575
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101755752023-05-13 Toward transplantation tolerance with adipose tissue-derived therapeutics Cheng, Hui-Yun Anggelia, Madonna Rica Lin, Cheng-Hung Wei, Fu-Chan Front Immunol Immunology Solid organ and composite tissue allotransplanation have been widely applied to treat end-stage organ failure and massive tissue defects, respectively. Currently there are a lot of research endeavors focusing on induction of transplantation tolerance, to relieve the burden derived from long-term immunosuppressant uptake. The mesenchymal stromal cells (MSCs) have been demonstrated with potent immunomodulatory capacities and applied as promising cellular therapeutics to promote allograft survival and induce tolerance. As a rich source of adult MSCs, adipose tissue provides additional advantages of easy accessibility and good safety profile. In recent years, the stromal vascular fraction (SVF) isolated from adipose tissues following enzymatic or mechanical processing without in vitro culture and expansion has demonstrated immunomodulatory and proangiogenic properties. Furthermore, the secretome of AD-MSCs has been utilized in transplantation field as a potential “cell-free” therapeutics. This article reviews recent studies that employ these adipose-derived therapeutics, including AD-MSCs, SVF, and secretome, in various aspects of organ and tissue allotransplantation. Most reports validate their efficacies in prolonging allograft survival. Specifically, the SVF and secretome have performed well for graft preservation and pretreatment, potentially through their proangiogenic and antioxidative capacities. In contrast, AD-MSCs were suitable for peri-transplantation immunosuppression. The proper combination of AD-MSCs, lymphodepletion and conventional immunosuppressants could consistently induce donor-specific tolerance to vascularized composite allotransplants (VCA). For each type of transplantation, optimizing the choice of therapeutics, timing, dose, and frequency of administration may be required. Future progress in the application of adipose-derived therapeutics to induce transplantation tolerance will be further benefited by continued research into their mechanisms of action and the development of standardized protocols for isolation methodologies, cell culture, and efficacy evaluation. Frontiers Media S.A. 2023-04-28 /pmc/articles/PMC10175575/ /pubmed/37187733 http://dx.doi.org/10.3389/fimmu.2023.1111813 Text en Copyright © 2023 Cheng, Anggelia, Lin and Wei https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Cheng, Hui-Yun
Anggelia, Madonna Rica
Lin, Cheng-Hung
Wei, Fu-Chan
Toward transplantation tolerance with adipose tissue-derived therapeutics
title Toward transplantation tolerance with adipose tissue-derived therapeutics
title_full Toward transplantation tolerance with adipose tissue-derived therapeutics
title_fullStr Toward transplantation tolerance with adipose tissue-derived therapeutics
title_full_unstemmed Toward transplantation tolerance with adipose tissue-derived therapeutics
title_short Toward transplantation tolerance with adipose tissue-derived therapeutics
title_sort toward transplantation tolerance with adipose tissue-derived therapeutics
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175575/
https://www.ncbi.nlm.nih.gov/pubmed/37187733
http://dx.doi.org/10.3389/fimmu.2023.1111813
work_keys_str_mv AT chenghuiyun towardtransplantationtolerancewithadiposetissuederivedtherapeutics
AT anggeliamadonnarica towardtransplantationtolerancewithadiposetissuederivedtherapeutics
AT linchenghung towardtransplantationtolerancewithadiposetissuederivedtherapeutics
AT weifuchan towardtransplantationtolerancewithadiposetissuederivedtherapeutics